Rescission/termination(s)

SPARC/Sec/SE/2026-27/14 June 25, 2026 National Stock Exchange of India Ltd., BSE Limited, Exchange Plaza, 5th Floor, Market Operations Dept. Plot No. C/1, G Block, P. J. Towers, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 051. Mumbai - 400 001. Scrip Symbol: SPARC Scrip Code: 532872 Dear Sir/ Madam, Sub: Intimation regarding Termination of License Agreement with CMS Bridging DMCC (CMS) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 This is with reference to the License Agreement dated November 05, 2019 entered into with CMS Bridging DMCC (“CMS”), has been mutually terminated by the parties on June 25, 2026. We would like to further inform that there is no material impact on the Company’s financial position, operations or other activities due to the termination of the agreement. The disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”) read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 for the above termination of License Agreement is provided in Annexure A. This is for your information and dissemination purpose. Yours faithfully, For Sun Pharma Advanced Research Company Ltd. Kajal Damania Company Secretary and Compliance Officer Annexure A Disclosure under Regulation 30 of SEBI LODR read with Sub para (5) of Para (B) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. a. Name(s) of parties with whom the CMS Bridging DMCC agreement is entered b. Purpose of entering into the agreement The purpose of the License Agreement was to develop and commercialize multiple products i.e XelprosTM, ElepsiaTM, TaclantisTM, PDP-716, SDN-037 in Mainland China, Hong Kong, Macao and Taiwan. c. Size of agreement Not Applicable d. Shareholding, if any, in the entity with Nil whom the agreement is executed e. Significant terms of the agreement (in Not Applicable brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc f. Whether, the said parties are related to None of the parties are related to promoter/promoter group/ group promoter/promoter group/ group companies in any manner. If yes, companies in any manner. nature of relationship g. Whether the transaction would fall No within related party transactions? If yes, whether the same is done at “arm’s length h. In case of issuance of shares to the Not Applicable parties, details of issue price, class of shares issued i. In case of loan agreements, details of Not Applicable lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis. j. Any other disclosures related to such Not Applicable agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc k. In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s) a) name of parties to the agreement; CMS Bridging DMCC b) nature of the agreement; Termination of Agreement c) date of execution of the agreement; June 25, 2026 d) details of amendment and impact The License Agreement with CMS has thereof or reasons of termination and been terminated mutually and there is no impact thereof. material impact on the Company’s financial position, operations or other activities due to the termination of the agreement. For Sun Pharma Advanced Research Company Ltd. Kajal Damania Company Secretary and Compliance Officer